C4 Therapeutics CCCC

$ 3.92 1.82%

Quarterly report 2024-Q3
added 10-31-2024

C4 Therapeutics Income Statement 2011-2024 | CCCC

Annual Income Statement C4 Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	438 M	300 M	1.48 B	1.47 B	-	-	-	-	-	-	-	-	-
Shares	49.6 M	48.9 M	46 M	40.8 M	-	-	-	-	-	-	-	-	-
Historical Prices	8.83	6.13	32.2	33.1	-	-	-	-	-	-	-	-	-
Net Income	-132 M	-128 M	-83.9 M	-66.3 M	-34.1 M	-15.7 M	-	-	-	-	-	-	-
Revenue	20.8 M	31.1 M	45.8 M	33.2 M	21.4 M	19.4 M	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	33.2 M	-	-	-	-	-	-	-	-	-
Operating Income	-139 M	-130 M	-82.1 M	-60.4 M	-35.5 M	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-137 M	-128 M	-80.6 M	-58.8 M	-33.9 M	-15.1 M	-	-	-	-	-	-	-
Operating Expenses	160 M	161 M	128 M	93.6 M	56.8 M	35.8 M	-	-	-	-	-	-	-
General and Administrative Expenses	42.1 M	42.8 M	33.3 M	15.2 M	8.77 M	7.16 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement C4 Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	69.6 M	68.8 M	68.4 M	60.5 M	49.2 M	49.1 M	49 M	49 M	48.9 M	48.8 M	48.7 M	48.7 M	48.5 M	43.9 M	43.1 M	43.1 M	1.54 M	1.48 M	1.46 M	1.43 M	1.38 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-24.7 M	-17.7 M	-28.4 M	-	-27 M	-35.9 M	-34.8 M	-	-32 M	-27.4 M	-31.6 M	-	-24.7 M	-22.6 M	-21 M	-	-21.8 M	-10.8 M	-11.9 M	-	-10.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	15.4 M	12 M	3.04 M	-	11.1 M	2.66 M	3.76 M	-	6.75 M	13.8 M	7.65 M	-	8.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-28.2 M	-21.4 M	-32.2 M	-	-27.8 M	-37.6 M	-36.2 M	-	-32.5 M	-27.4 M	-31.4 M	-	-24.3 M	-22.1 M	-20.5 M	-	-18.3 M	-10.9 M	-12.3 M	-	-10 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	43 K	-	-	-	-1 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-27.9 M	-21.1 M	-31.8 M	-	-27.4 M	-37.1 M	-35.7 M	-	-32.1 M	-26.9 M	-31.1 M	-	-23.9 M	-21.7 M	-20.1 M	-	-17.9 M	-10.4 M	-11.9 M	-	-8.83 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	43.6 M	33.4 M	35.3 M	-	38.9 M	40.2 M	40 M	-	39.2 M	41.2 M	39 M	-	32.8 M	31.9 M	27.9 M	-	26.8 M	20.5 M	19.2 M	-	15.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	11.8 M	9.7 M	10.3 M	-	10.5 M	10.3 M	10.9 M	-	9.58 M	9.9 M	12.8 M	-	8.45 M	8.61 M	7.41 M	-	2.86 M	2.77 M	2.84 M	-	2.42 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency